WO2007081510-A3  SLEIJFER D T ET AL: "PHASE II STUDY OF SUBCUTANEOUS INTERLEUKIN-2 IN UNSELECTED PATIENTS WITH ADVANCED RENAL CELL CANCER ON AN OUTPATIENT BASIS" JOURNAL OF CLINICAL ONCOLOGY, vol. 10, no. 7, 1992, pages 1119-1123, XP002405029 ISSN: 0732-183X;  DATABASE INTEGRITY [Online] Prous Science; Proc Am Soc Clin Oncol (ASCO) 22: Abst 1556, 2003, AMATO ET AL.: "Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC)" XP002405104;  VERRA N ET AL: "Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma." BRITISH JOURNAL OF CANCER, vol. 88, no. 9, 6 May 2003 (2003-05-06), pages 1346-1351, XP002405030 ISSN: 0007-0920;  NAGLER RAFAEL M ET AL: "The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma" ARCHIVES OF ORAL BIOLOGY, vol. 46, no. 6, June 2001 (2001-06), pages 487-493, XP002405031 ISSN: 0003-9969;  ANGEVIN ERIC ET AL: "Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer" JOURNAL OF IMMUNOTHERAPY WITH EMPHASIS ON TUMOR IMMUNOLOGY, vol. 18, no. 3, 1995, pages 188-195, XP002405032 ISSN: 1067-5582;  SLEIJFER D T ET AL: "PHASE II STUDY OF SUBCUTANEOUS INTERLEUKIN-2 IN UNSELECTED PATIENTS WITH ADVANCED RENAL CELL CANCER ON AN OUTPATIENT BASIS", JOURNAL OF CLINICAL ONCOLOGY, vol. 10, no. 7, 1992, pages 1119 - 1123, XP002405029, ISSN: 0732-183X,relevantClaims[1-30],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;1119&lt;/pp&gt;&lt;column&gt;L&lt;/column&gt;&lt;ppl&gt;1119&lt;/ppl&gt;&lt;coll&gt;R&lt;/coll&gt;&lt;linel&gt;1&lt;/linel&gt;&lt;table&gt;1,3&lt;/table&gt;];  DATABASE INTEGRITY Prous Science; 2003, AMATO ET AL.: "Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC)", XP002405104,relevantClaims[1-30],relevantPassages[&lt;column&gt;A&lt;/column&gt;];  VERRA N ET AL: "Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.", BRITISH JOURNAL OF CANCER, vol. 88, no. 9, 6 May 2003 (2003-05-06), pages 1346 - 1351, XP002405030, ISSN: 0007-0920,relevantClaims[1-30],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;1346&lt;/pp&gt;];  NAGLER RAFAEL M ET AL: "The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma", ARCHIVES OF ORAL BIOLOGY, vol. 46, no. 6, June 2001 (2001-06-01), pages 487 - 493, XP002405031, ISSN: 0003-9969,relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;488&lt;/pp&gt;&lt;column&gt;R&lt;/column&gt;&lt;line&gt;1-3&lt;/line&gt;];  ANGEVIN ERIC ET AL: "Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer", JOURNAL OF IMMUNOTHERAPY WITH EMPHASIS ON TUMOR IMMUNOLOGY, vol. 18, no. 3, 1995, pages 188 - 195, XP002405032, ISSN: 1067-5582,relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;189&lt;/pp&gt;&lt;column&gt;R&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;192&lt;/pp&gt;&lt;column&gt;R&lt;/column&gt;&lt;para&gt;L&lt;/para&gt;]EP1964165-A2  AMETOWABLA M ET AL: "Laser processing of crystalline silicon solar cells", CONFERENCE RECORD OF THE THIRTY-FIRST IEEE PHOTOVOLTAIC SPECIALIST CONFERENCE (IEEE CAT. NO. 05CH37608) IEEE PISCATAWAY, NJ, USA,, 3 January 2005 (2005-01-03), pages 1277-1280, XP010822989, DOI: 10.1109/PVSC.2005.1488373 ISBN: 978-0-7803-8707-2;  See also references of WO 2007081510A2